Indication
Renal Cell Cancer
27 clinical trials
33 products
12 drugs
Clinical trial
A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin LymphomaStatus: Terminated, Estimated PCD: 2023-02-13
Product
NIR178Product
PDR001Clinical trial
A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic CancersStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Product
AlintegimodProduct
IpilimumabProduct
NivolumabClinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORSStatus: Terminated, Estimated PCD: 2022-10-14
Product
PF-07263689Product
SasanlimabProduct
DNX-2440Clinical trial
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver MetastasisStatus: , Estimated PCD: 2026-07-31
Clinical trial
Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-05-14
Product
TT-10Product
Modi-1/Modi-1vClinical trial
A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients With Breast, Head and Neck, Ovarian, or Renal CancerStatus: Recruiting, Estimated PCD: 2026-04-04
Clinical trial
A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-08-31
Product
PembrolizumabProduct
BelzutifanProduct
CabozantinibProduct
AvelumabClinical trial
A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMAStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Product
AxitinibProduct
SunitinibProduct
CPI-006Clinical trial
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERSStatus: Completed, Estimated PCD: 2022-12-28
Product
CPI-006 + PembrolizumabClinical trial
Phase I/II Study of Aerosol Interleukin-2 for Pulmonary MetastasesStatus: Active (not recruiting), Estimated PCD: 2026-04-30
Product
AldesleukinClinical trial
89Zr-DFO-GmAb PET/CT vs Contrast-Enhanced CT for Detection of Recurrent Clear Cell Renal Cell Carcinoma After SurgeryStatus: Not yet recruiting, Estimated PCD: 2029-06-01
Product
GirentuximabClinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-31
Drug
CeralasertibProduct
OlaparibProduct
DurvalumabClinical trial
Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Product
Enzyme InhibitorClinical trial
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2019-05-22
Drug
interleukin-2Product
EntinostatClinical trial
A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell CarcinomaStatus: Terminated, Estimated PCD: 2022-07-26
Drug
T-VECDrug
mFOLFOX6Clinical trial
WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell CancerStatus: Recruiting, Estimated PCD: 2025-11-30
Product
CediranibDrug
AN0025Clinical trial
Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted TherapyStatus: Completed, Estimated PCD: 2022-09-06
Drug
SitravatinibClinical trial
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following MetastatectomyStatus: Active (not recruiting), Estimated PCD: 2018-07-17
Product
PazopanibClinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing CancersStatus: Recruiting, Estimated PCD: 2027-01-01
Drug
cyclophosphamideDrug
fludarabineDrug
IL-2Clinical trial
A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in TumorigenesisStatus: Active (not recruiting), Estimated PCD: 2020-02-14
Product
Akt Inhibitor MK2206Product
HydroxychloroquineClinical trial
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)Status: Active (not recruiting), Estimated PCD: 2023-05-24
Clinical trial
A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment BiopsyStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Drug
AtezolizumabDrug
LurbinectedinClinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung CancerStatus: Completed, Estimated PCD: 2018-06-05
Drug
pembrolizumabClinical trial
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)Status: Active (not recruiting), Estimated PCD: 2023-10-02
Product
CrizotinibProduct
Savolitinib